Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Galen HRT Ring Femring Will Be Approved By February Or March, CEO Predicts

Executive Summary

Galen's estradiol ring product Femring will be approved by FDA in February or March, CEO Roger Boissonneault said in an earnings call Feb. 11

You may also be interested in...



Galen Femring Includes HRT Class Labeling; Launch In June

Labeling for Galen's vaginal hormone therapy Femring follows the template established for Wyeth's Premarin family to incorporate the findings from NIH's Women's Health Initiative study

Galen Femring Includes HRT Class Labeling; Launch In June

Labeling for Galen's vaginal hormone therapy Femring follows the template established for Wyeth's Premarin family to incorporate the findings from NIH's Women's Health Initiative study

Hormone Therapy Class Labeling Uses Wyeth Template; Appeals Due By March

Sponsors of hormone replacement therapies have two months to pull together data to justify exemptions to FDA's proposed class labeling incorporating risk information from the Women's Health Initiative

Related Content

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel